BioRealm Press Release 2015
3
Overview News & Events Investors SEC Filings Stock Information Press Releases Event Calendar Leadership Webcast Archive Stockholder FAQs Analyst Coverage E-mail Alerts Information Request Annual Meeting Materials Stockholder Electronic Delivery Contact Us Toolkit Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Stock Quote Home > About Affymetrix > Investors > Press Release Press Release View printer-friendly version << Back Genotyping Begins on NIDA’s Biorepository of Over 50,000 Samples – Affymetrix, BioRealm, and RUCDR Infinite Biologics Team up to Help Study the Genetics of Addiction SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 7, 2015-- Affymetrix, Inc. (NASDAQ:AFFX), BioRealm, LLC, and RUCDR Infinite Biologics today announced a broad strategic alliance. This alliance will leverage BioRealm's SmokeScreen platform to genotype the National Institute on Drug Abuse (NIDA) biorepository of more than 50,000 samples, collected from human subjects studied in NIDA-funded research. NIDA preserves these samples in a biorepository at RUCDR Infinite Biologics, on the campus of Rutgers University. The biorepository is maintained by RUCDR Infinite Biologics and in part through collaboration with the BioProcessing Solutions Alliance which was created by RUDCR Infinite Biologics and BioStorage Technologies, the global leader in comprehensive sample management. Once the genetic information contained in these samples is made available to researchers, it will be extremely valuable for studying the link between genetic variations and addiction. Detailed genetic information might, for example, be used by researchers exploring how genetics influences patients’ individual responses to treatment approaches. To date, the genetic information contained in these samples has been focused on specific targets and not collectively analyzed. This strategic alliance makes it possible, for the first time ever, to cost-efficiently analyze this valuable information. The genetic information will be obtained by using BioRealm’s SmokeScreen array, developed in conjunction with NIDA’s Genetics Consortium and Affymetrix. SmokeScreen array is a genome-wide array with research-driven focus on more than 1,000 addiction-related genes. BioRealm’s Co-Founder Dr. James Baurley remarked, “We are extremely honored to have the help and support of Affymetrix and RUCDR. Our SmokeScreen technology provides a suite of genomic research tools to scientists working on addiction – one of the biggest public health threats. Because of our partners’ confidence in our technology, it will be made available to scientific teams around the world who are working on these critical health issues.” ® ® ® ® JP CN Home Home Products Products Brands Brands Community Community Support Support Partners & Programs Partners & Programs About Affymetrix About Affymetrix Careers Careers NetAffx NetAffx Convert html to pdf online with PDFmyURL
-
Upload
brian-malone -
Category
Documents
-
view
82 -
download
0
Transcript of BioRealm Press Release 2015
Overview
News & Events
Investors
SEC Filings
Stock Information
Press Releases
Event Calendar
Leadership
Webcast Archive
Stockholder FAQs
Analyst Coverage
E-mail Alerts
Information Request
Annual Meeting Materials
Stockholder ElectronicDelivery
Contact Us
Toolkit
Print PageE-mail PageRSS FeedsE-mail AlertsIR Contacts
Stock Quote
Home > About Affymetrix > Investors > Press Release
Press Release
View printer-friendly version << Back
Genotyping Begins on NIDA’s Biorepository of Over 50,000 Samples – Affymetrix, BioRealm, and RUCDR InfiniteBiologics Team up to Help Study the Genetics of Addiction
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 7, 2015-- Affymetrix, Inc. (NASDAQ:AFFX), BioRealm, LLC, and RUCDR InfiniteBiologics today announced a broad strategic alliance. This alliance will leverage BioRealm's SmokeScreen platform to genotype
the National Institute on Drug Abuse (NIDA) biorepository of more than 50,000 samples, collected from human subjects studiedin NIDA-funded research. NIDA preserves these samples in a biorepository at RUCDR Infinite Biologics, on the campus of RutgersUniversity. The biorepository is maintained by RUCDR Infinite Biologics and in part through collaboration with the BioProcessingSolutions Alliance which was created by RUDCR Infinite Biologics and BioStorage Technologies, the global leader in comprehensivesample management.
Once the genetic information contained in these samples is made available to researchers, it will be extremely valuable forstudying the link between genetic variations and addiction. Detailed genetic information might, for example, be used byresearchers exploring how genetics influences patients’ individual responses to treatment approaches.
To date, the genetic information contained in these samples has been focused on specific targets and not collectively analyzed.This strategic alliance makes it possible, for the first time ever, to cost-efficiently analyze this valuable information. The geneticinformation will be obtained by using BioRealm’s SmokeScreen array, developed in conjunction with NIDA’s Genetics Consortium
and Affymetrix. SmokeScreen array is a genome-wide array with research-driven focus on more than 1,000 addiction-related
genes.
BioRealm’s Co-Founder Dr. James Baurley remarked, “We are extremely honored to have the help and support of Affymetrix andRUCDR. Our SmokeScreen technology provides a suite of genomic research tools to scientists working on addiction – one of the
biggest public health threats. Because of our partners’ confidence in our technology, it will be made available to scientific teamsaround the world who are working on these critical health issues.”
®
®
®
®
JP CNHomeHome ProductsProducts BrandsBrands CommunityCommunity SupportSupport Partners & ProgramsPartners & Programs About AffymetrixAbout Affymetrix CareersCareers NetAffxNetAffx
Convert html to pdf online with PDFmyURL
SecurityAFFX (Common Stock)$13.85 (0.00%Current Day's High13.86Current Day's Low13.83Current Day's Volume3,789,397Last TradeJan 22 16 4:00 p.m. ETExchangeNASDAQThe stock priceperformance shown onthe quote above is notnecessarily indicative offuture price performance
RUCDR Infinite Biologics’ Chief Operating Officer and Director of Technology Development Dr. Andrew Brooks said, “Because of theSmokeScreen array, we have the ability to reveal genetic information previously hidden in NIDA's samples. We have great
confidence in SmokeScreen ‒ it is a validated platform that will become a crucial tool in advancing addiction research and moving
the field towards personalized treatment.”
According to Dr. Frank R. Witney, President and Chief Executive Officer of Affymetrix, “We are excited to be part of BioRealm’svision of improving human health by providing insight into the genetics of tobacco-related illness. It was a pleasure to work withBioRealm’s team of dedicated scientists to co-develop this cutting-edge technology.”
About BioRealm LLC
BioRealm, a life sciences company headquartered in Monument, Colorado, uses novel technology to provide end-to-end servicesfor researchers and product development teams, including study design, data management, and data analysis. BioRealm’s cutting-edge products and technologies support the research process, from hypothesis to conclusion. BioRealm’s SmokeScreen platform
provides researchers with unique insight into the genetics of addiction, smoking behavior, and treatment approaches. Read moreat http://biorealmresearch.com/.
About RUCDR Infinite Biologics
RUCDR Infinite Biologics offers a complete and integrated selection of biological sample processing, analysis and biorepositoryservices to government agencies, academic institutions, foundations, and biotechnology and pharmaceutical companies within theglobal scientific community. RUCDR provides DNA, RNA, and cell lines with clinical data to hundreds of research laboratories forstudies on mental health and developmental disorders, drug and alcohol abuse, diabetes and digestive, liver, and kidney diseases.A unit of Rutgers University’s Human Genetics Institute of New Jersey, RUCDR is the world’s largest university-basedbiorepository. In 2012, a Bioprocessing Solutions Alliance was created between RUCDR and BioStorage Technologies to provideresearch companies and organizations with a state-of-the-art scientific and technology infrastructure for the delivery of advancedsample bioprocessing and biobanking solutions. Read more at www.rucdr.org.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level,facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. Affymetrixprovides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as wellas leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been publishedciting Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities inCleveland, Ohio, San Diego, Vienna, and Singapore. Affymetrix has about 1,100 employees worldwide and maintains sales anddistribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visitwww.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E ofthe Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes,""intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results todiffer materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the
®
®
®
Convert html to pdf online with PDFmyURL
year ended December 31, 2014, and other SEC reports for subsequent quarterly periods.
PLEASE NOTE: Affymetrix and the Affymetrix logo trademarks are the property of Affymetrix, Inc. All other trademarks are theproperty of their respective owners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150707005447/en/
Source: Affymetrix, Inc.
AffymetrixMedia Contact:Mindy Lee-Olsen, 408-731-5523Vice President, Marketing [email protected] Contact:Doug Farrell, 408-731-5285Vice President, Investor [email protected] M. Malone, [email protected] Infinite BiologicsEdward F. Tate III, 848-445-3153Director of [email protected]
Data provided by Nasdaq. Minimum 15 minutes delayed.
Back to Top >
© 2011 Affymetrix, Inc. All rights reserved. Contact Us | Help | Terms of Use | Privacy Policy
Convert html to pdf online with PDFmyURL
